title: Adoptive transfer of cytomegalovirus/Epstein-Barr virus-specific immune effector cells for therapeutic and preventive/preemptive treatment of pediatric allogeneic cell transplant recipients.
abstract: This report describes a safe and effective therapy through adoptive transfer of donor cytomegalovirus (CMV)/Epstein-Barr virus (EBV) immune effector cells. The patients, from 3 to 10 years of age, suffering from hematologic diseases received haploidentical transplantation. All 3 patients developed varying levels of viremia from days 13 to 31 and 2 patients developed CMV-interstitial pneumonitis or interstitial inflammation after transplantation. Tapering down the dose of immunosuppressives together with intensive antivirus therapy and escalated infusions of donor-derived CMV/EBV immune effector cells effectively controlled virus-related diseases. All 3 patients survived and remained CMV/EBV-free 14-16 months after transplantation.
authors.affiliation: Fu Dan University, Institute of Hematology, Shanghai Dao-Pei Hospital, Minhang County, Shanghai, China.
authors.forename: Lujia
authors.initials: L
authors.lastname: Dong
authors.forename: Zhi-Yong
authors.initials: ZY
authors.lastname: Gao
authors.forename: Lung-Ji
authors.initials: LJ
authors.lastname: Chang
authors.forename: Yin
authors.initials: Y
authors.lastname: Liang
authors.forename: Xi-You
authors.initials: XY
authors.lastname: Tan
authors.forename: Jin-Hong
authors.initials: JH
authors.lastname: Liu
authors.forename: Xin-Jian
authors.initials: XJ
authors.lastname: Yu
authors.forename: Fu-Hung
authors.initials: FH
authors.lastname: Yang
authors.forename: Yi
authors.initials: Y
authors.lastname: Xie
authors.forename: Dao-Pei
authors.initials: DP
authors.lastname: Lu
mesh_terms: D019264:Adoptive Transfer / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000517:prevention & control; D003713:Dendritic Cells / Q000637:transplantation / Q000821:virology; D020031:Epstein-Barr Virus Infections / Q000209:etiology / Q000517:prevention & control; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D008297:Male; D011292:Premedication / Q000379:methods*; D015996:Survival Rate; D013602:T-Lymphocytes, Cytotoxic / Q000637:transplantation / Q000821:virology; D016896:Treatment Outcome